Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 443

1.

Critical appraisal of clinical trials in multiple system atrophy: Toward better quality.

Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ; Movement Disorders Society MSA Study Group.

Mov Disord. 2017 Aug 7. doi: 10.1002/mds.27080. [Epub ahead of print] Review.

PMID:
28782838
2.

New perspectives on study designs for evaluating neuroprotection in Parkinson's disease.

Thibault L, Rascol O, Corvol JC, Ferreira J, Defebvre L, Deplanque D, Bordet R, Moreau C, Devos D.

Mov Disord. 2017 Jul 13. doi: 10.1002/mds.27055. [Epub ahead of print] No abstract available.

PMID:
28703395
3.

Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohorts.

Liu G, Locascio JJ, Corvol JC, Boot B, Liao Z, Page K, Franco D, Burke K, Jansen IE, Trisini-Lipsanopoulos A, Winder-Rhodes S, Tanner CM, Lang AE, Eberly S, Elbaz A, Brice A, Mangone G, Ravina B, Shoulson I, Cormier-Dequaire F, Heutink P, van Hilten JJ, Barker RA, Williams-Gray CH, Marinus J, Scherzer CR; HBS; CamPaIGN; PICNICS; PROPARK; PSG; DIGPD; PDBP.

Lancet Neurol. 2017 Aug;16(8):620-629. doi: 10.1016/S1474-4422(17)30122-9. Epub 2017 Jun 16.

PMID:
28629879
4.

Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes.

Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A.

J Am Med Dir Assoc. 2017 Sep 1;18(9):791-796. doi: 10.1016/j.jamda.2017.04.014. Epub 2017 Jun 13.

PMID:
28623157
5.

Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson's disease treated with L-DOPA.

Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W.

Expert Rev Neurother. 2017 Jul;17(7):649-659. doi: 10.1080/14737175.2017.1336086. Epub 2017 Jun 5.

PMID:
28580819
6.

Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ; Preladenant Early Parkinson Disease Study Group.

Neurology. 2017 Jun 6;88(23):2198-2206. doi: 10.1212/WNL.0000000000004003. Epub 2017 May 10.

PMID:
28490648
7.

Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P; BIPARK-2 Study Investigators.

JAMA Neurol. 2017 Feb 1;74(2):197-206. doi: 10.1001/jamaneurol.2016.4703.

PMID:
28027332
8.

Ergot and non-ergot dopamine agonists and heart failure in patients with Parkinson's disease.

Montastruc F, Moulis F, Araujo M, Chebane L, Rascol O, Montastruc JL.

Eur J Clin Pharmacol. 2017 Jan;73(1):99-103. doi: 10.1007/s00228-016-2142-x. Epub 2016 Oct 27.

PMID:
27796464
9.

Characterization of Burning Mouth Syndrome in Patients with Parkinson's Disease.

Bonenfant D, Rompré PH, Rei N, Jodoin N, Soland VL, Rey V, Brefel-Courbon C, Ory-Magne F, Rascol O, Blanchet PJ.

J Oral Facial Pain Headache. 2016 Fall;30(4):318-322. doi: 10.11607/ofph.1691.

PMID:
27792799
10.

A genome-wide association study in multiple system atrophy.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O'Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.

Neurology. 2016 Oct 11;87(15):1591-1598. Epub 2016 Sep 14.

11.

Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Liu G, Boot B, Locascio JJ, Jansen IE, Winder-Rhodes S, Eberly S, Elbaz A, Brice A, Ravina B, van Hilten JJ, Cormier-Dequaire F, Corvol JC, Barker RA, Heutink P, Marinus J, Williams-Gray CH, Scherzer CR; International Genetics of Parkinson Disease Progression (IGPP) Consortium.

Ann Neurol. 2016 Nov;80(5):674-685. doi: 10.1002/ana.24781.

12.

An original pharmacoepidemiological-pharmacodynamic method: application to antipsychotic-induced movement disorders.

Nguyen TT, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F.

Br J Clin Pharmacol. 2017 Mar;83(3):612-622. doi: 10.1111/bcp.13145. Epub 2016 Nov 6.

PMID:
27687785
13.

Long-term effects of rasagiline and the natural history of treated Parkinson's disease.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW; AFU Investigators.

Mov Disord. 2016 Oct;31(10):1489-1496. doi: 10.1002/mds.26724.

PMID:
27431201
14.

Unmasking levodopa resistance in Parkinson's disease.

Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR.

Mov Disord. 2016 Nov;31(11):1602-1609. doi: 10.1002/mds.26712. Epub 2016 Jul 19. Review.

PMID:
27430479
15.

Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.

Perez-Lloret S, Rascol O.

CNS Drugs. 2016 Aug;30(8):703-17. doi: 10.1007/s40263-016-0360-5. Review.

PMID:
27344665
16.

French consensus procedure for assessing cognitive function in Parkinson's disease.

Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O; NS-Park network.

Rev Neurol (Paris). 2016 Nov;172(11):696-702. doi: 10.1016/j.neurol.2016.05.001. Epub 2016 Jun 16.

PMID:
27318613
17.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
18.

Atropinic (Anticholinergic) Burden in Parkinson's Disease.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F.

Mov Disord. 2016 May;31(5):632-6. doi: 10.1002/mds.26595. Epub 2016 Mar 29.

PMID:
27028036
19.

Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials.

Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O.

Front Neurol. 2016 Mar 8;7:27. doi: 10.3389/fneur.2016.00027. eCollection 2016.

20.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766

Supplemental Content

Loading ...
Support Center